A Longitudinal Study of Medicaid Coverage for Tobacco Dependence Treatments in Massachusetts and Associated Decreases in Hospitalizations for Cardiovascular Disease
Authors:
Open Access
- 7 December 2010
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 7 (12) , e1000375
Abstract
Insurance coverage of tobacco cessation medications increases their use and reduces smoking prevalence in a population. However, uncertainty about the impact of this coverage on health care utilization and costs is a barrier to the broader adoption of this policy, especially by publicly funded state Medicaid insurance programs. Whether a publicly funded tobacco cessation benefit leads to decreased medical claims for tobacco-related diseases has not been studied. We examined the experience of Massachusetts, whose Medicaid program adopted comprehensive coverage of tobacco cessation medications in July 2006. Over 75,000 Medicaid subscribers used the benefit in the first 2.5 years. On the basis of earlier secondary survey work, it was estimated that smoking prevalence declined among subscribers by 10% during this period. Using claims data, we compared the probability of hospitalization prior to use of the tobacco cessation pharmacotherapy benefit with the probability of hospitalization after benefit use among Massachusetts Medicaid beneficiaries, adjusting for demographics, comorbidities, seasonality, influenza cases, and the implementation of the statewide smoke-free air law using generalized estimating equations. Statistically significant annualized declines of 46% (95% confidence interval 2%–70%) and 49% (95% confidence interval 6%–72%) were observed in hospital admissions for acute myocardial infarction and other acute coronary heart disease diagnoses, respectively. There were no significant decreases in hospitalizations rates for respiratory diagnoses or seven other diagnostic groups evaluated. Among Massachusetts Medicaid subscribers, use of a comprehensive tobacco cessation pharmacotherapy benefit was associated with a significant decrease in claims for hospitalizations for acute myocardial infarction and acute coronary heart disease, but no significant change in hospital claims for other diagnoses. For low-income smokers, removing the barriers to the use of smoking cessation pharmacotherapy has the potential to decrease short-term utilization of hospital services. Please see later in the article for the Editors' SummaryKeywords
This publication has 21 references indexed in Scilit:
- Hospital Admissions for Acute Myocardial Infarction, Angina, Stroke, and Asthma After Implementation of Arizona's Comprehensive Statewide Smoking BanAmerican Journal of Public Health, 2011
- The Impact of Massachusetts’ Smoke-Free Workplace Laws on Acute Myocardial Infarction DeathsAmerican Journal of Public Health, 2010
- Medicaid Coverage for Tobacco Dependence Treatments in Massachusetts and Associated Decreases in Smoking PrevalencePLOS ONE, 2010
- Declines in Hospital Admissions for Acute Myocardial Infarction in New York State After Implementation of a Comprehensive Smoking BanAmerican Journal of Public Health, 2007
- Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjectsEuropean Heart Journal, 2007
- Reversal of risk upon quitting smokingThe Lancet, 2006
- Changes in health care costs before and after smoking cessationNicotine & Tobacco Research, 2006
- Smoking Cessation Attempts in Relation to Prior Health Care Charges: The Effect of Antecedent Smoking-Related Symptoms?American Journal of Health Promotion, 2003
- Socioeconomic Status and Health: The Potential Role of Environmental Risk ExposureAnnual Review of Public Health, 2002
- Use and Cost Effectiveness of Smoking-Cessation Services under Four Insurance Plans in a Health Maintenance OrganizationNew England Journal of Medicine, 1998